This video covers gastric NETs. We first delineate NETs from other tumors that arise from the stomach (eg adenocarcinoma, GISTs). Then we discuss the origin of NETs from gastric enterochromaffin cells. We cover the three different types of gastric NETs and the underlying pathophysiology of each one. We then cover how the different pathophysiology leads to different treatment strategies.

These videos are for educational purposes only, do not use to diagnose or treat any diseases. This is not clinical advice.

Nitya Raj, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses emerging treatment options for patients with neuroendocrine tumors (NETs) located in the gastrointestinal tract. Whilst there are a number of therapies such as radiopharmaceutical treatments currently available, clinicians need to elucidate which therapies are suited for a particular patient. Prospective data from the Phase II ECOG-ACRIN E2211 trial (NCT01824875) have additionally assessed the role of capecitabine and temozolomide in patients with pancreatic NETs. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

In this video, we will discuss the pathological features of Neuroendocrine tumors of GIT

In the dynamic world of diagnosing and treating people living with neuroendocrine tumors (NETs), four expert physicians discuss everything from the increased incidence of NETs to symptoms of the disease and how to live with NETs for many years. What is unique about NETs? Where do NETs form in the body? What are the most recent advances in imaging and treatment options? Dr. Emily Bergsland, Dr. Pamela Kunz, Dr. Rodney Pommier, and Dr. Edward Wolin provide an overview about this uncommon cancer and offer patients perspectives from key opinion leaders in the field.

A great introduction to NETs. Watch this 15-minute presentation from a leading NET physician. Learn about complex terms and abbreviations. Find out about how tumors are graded and which ones are the most aggressive. See the different types of treatments used including surgery, targeted therapies, nuclear medicine and interventional radiology. Filmed Feb 2017.

Bahar Laderian, MD, Cleveland Clinic, Cleveland, OH, discusses how primary site, stage, and surgery can influence overall survival (OS) in gastrointestinal (GI) neuroendocrine tumors (NETs). Patients from a database were analyzed, and OS was improved in patients with stage IV, localized tumors who received surgery, especially in patients with pancreatic and gastric NETs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.